EASL Recommendations on Treatment of Hepatitis C 2014New guidelines for hepatitis C by European Medicines Agency (EMA) was released today at the EASL International Liver Congress 2014 meeting, the World Health Organization (WHO) issued its first guidance for the treatment of hepatitis C earlier this week.
According to an article published yesterday at Medscape Medical News; Jean-Michel Pawlotsky, MD, PhD, director of the French National Reference Centre for Viral Hepatitis stated that this new EASL document constitutes recommendations rather than guidelines because of the need to circumvent the traditional long guideline development process, which "doesn't fit the HCV field any longer."
In addition, Dr. Stefan Z. Wiktor noted both documents are expected to be revised soon. "It's such a rapidly moving field that, even as we were developing the guidelines, we had to modify our schedule to include recommendations on the newest drugs,"
EASL Recommendations on Treatment of Hepatitis C 2014
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC)
(read more by viewing or downloading EASL recommendations)
Full version:
EASL Recommendations on Treatment of Hepatitis C 2014
(download pdf)
Summary:
EASL Recommendations on Treatment of Hepatitis C 2014(download pdf)
No comments:
Post a Comment